Dec-15 -

Leukemia Group / Elderly

EORTC 06011 – Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10% blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for intensive therapy.

An EORTC-German MDS Study Group randomized phase III study.

This EORTC study established the efficacy and safety of treatment with decitabine, in elderly patients with higher-risk Myelodysplastic Syndrome (MDS).


Go to Top